Navigation Links
Experimental Vaccine Halts Prostate Cancer in Mice
Date:2/1/2008

Human trials may start in two years, California researcher says

FRIDAY, Feb. 1 (HealthDay News) -- An experimental prostate cancer vaccine has stopped the progress of the disease in 90 percent of the mice who got it, California researchers report.

"The vaccine turned the cancer into a chronic, manageable disease," said W. Martin Kast, lead author of a report published in the Feb. 1 issue of Cancer Research.

Twenty mice, genetically bred to develop prostate cancer, were given the vaccine in a two-step process, said Kast, a professor of molecular microbiology and immunology at the University of Southern California, Los Angeles.

When the mice were 8 weeks old, they got one injection consisting of a fragment of DNA that coded for prostate stem cell antigen (PSCA), a protein that is overproduced as prostate cancers grow. That injection alerted the immune system, Kast said.

A second shot, given two weeks later, used a modified horse virus to deliver the gene for PSCA, throwing the immune system into full action against the tumor.

Only two of the 20 vaccinated mice developed full-blown prostate cancer at the end of one year. Twenty other similarly bred mice who did not get the vaccine died of their cancers.

A vaccine for prostate cancer already exists, but it is only designed to extend survival for men in advanced stages of the disease and it has not been approved for use in the United States.

The new vaccine is designed to be used much earlier, Kast said. "Our vaccine approach would be to give it before you actually develop the disease," he said. Candidates for vaccination would be men who have high levels of prostate-specific antigen (PSA), a protein associated with the cancer.

Physicians now perform biopsies in most such cases, looking for evidence of cancer, which is usually inconclusive. The vaccine could be given instead of the "watchful waiting" now common fo
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
10. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
11. Vaccine Stops Alzheimers Brain Tangles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) ... owing to novel medical indications created and due to ... societies where physical appearance is extremely valued. Although the ... competitors, new companies and technologies are setting ground for ... put the price of 1st-gen products under pressure, only ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, ... invasive procedure known as morcellation carries a risk of spreading ... more clearly. Twenty-seven of every 10,000 women who had ... the procedure, researchers found, with the odds being highest for ... hysterectomy with morcellation use a power cutter to slice uterine ...
(Date:7/22/2014)... French . Montreal, ... step out for a cigarette twice as often as smokers ... who have the hardest time shaking off the habit may ... of. , Those insights were among the collective findings recently ... by a team of researchers based in part at Concordia ...
(Date:7/22/2014)... 22, 2014 5i Sciences, a medical ... appointment of Molly Coye, M.D., M.P.H. to a role ... renowned authority on the market introduction of innovative technologies ... she will advise on strategies for building a successful ... technology. Dr. Coye is currently the Chief Innovation ...
(Date:7/22/2014)... 2014 The Latin America Drilling fluid and ... and completion fluid market in Latin America with analysis and ... in Latin America is estimated to grow from around $0.93 ... CAGR of 9.2%, for the given period. , Browse through ... fluid Market Report, to get an idea of the in-depth ...
Breaking Medicine News(10 mins):Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 6
... Announces 2008,Journalistic Achievement Awards, NEW YORK, May ... Show are among winners receiving top honors,in the ... for Aesthetic Plastic Surgery (ASAPS). Selected from among ... their awards on May,6th, at ASAPS, Annual Meeting ...
... $12.5 million private placement, SHANGHAI, China, May ... or "ATG") (OTC Bulletin Board: AAXT),today announced that, ... of all the outstanding common stock of Asian ... ("ABM"),pursuant to a share exchange agreement. ATG acquired ...
... Many women under age 55 arent seeking timely treatment for ... reaction to follow a Hollywood script tightening in the ... one knee. , Thats the finding of researchers who presented ... on Quality of Care and Outcomes Research (QCOR) in Cardiovascular ...
... Finding could help men with precancerous lesions avoid unnecessary ... Spanish researchers report they may have found a way ... develop into cancer. , The findings, published in the ... show a link between high-grade prostatic intraepithelial neoplasia (HG-PIN) ...
... Wound Closure System earns high marks from ... combat surgeons, ... U.S. Army combat support surgeons in Baghdad show that a new,medical device ... and limbs of soldiers and civilians., A team of battle zone ...
... the Decade Announced at Special 10th Anniversary ... Ceremony in Washington, DC -, ... honor six inspiring winners at the 10th annual Welcome Back Awards,ceremony ... the,Welcome Back Awards has recognized individuals for their outstanding,commitments to mental ...
Cached Medicine News:Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 2Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 3Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 2Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 3Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 4Health News:Some women more likely to miss or ignore heart attack warning signs 2Health News:Some women more likely to miss or ignore heart attack warning signs 3Health News:Biomarker Spots Which Lesions Likely to Progress to Prostate Cancer 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 3Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 2Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 3Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 4Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 5Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 6
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)...  According to the American Optometric Association (AOA), parents ... devices. An AOA survey reports that 83 percent of ... they use an electronic device for three or more ... parents revealed that only 40 percent of parents believe ... amount of time. Eye doctors are concerned that this ...
(Date:7/22/2014)... MARCOS, Texas , July 22, 2014 Quantum Materials ... and Mr. John Heaton to the Board of ... by Dr. Ghassan Jabbour , QMC Chief Science Officer and ... Michael Wong of Rice University and Mr. Tomio ... Japan . " Quantum Materials welcomes ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Pharmaceuticals, Inc. announced today that the U.S. Food ... drug status for the treatment of pancreatic cancer. ... the marketed chemotherapy drug irinotecan.  MM-398 is partnered ... Taiwan under the designation PEP02. (Logo: ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... the NASDAQ Global Select Market closes on Tuesday, August 9, ... Executive Officer, will host a conference call and webcast at ... the financial results for the second quarter 2011 and to ...
Cached Medicine Technology:FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 3
... stools come with five legs for extra ... 25" (total vertical travel 6"). 2" ball ... and fire retardant upholstery, available in black ... special order. Features a contoured, padded, upholstered ...
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Medicine Products: